Revenue growth has stalled at 0.0% in 2026Q2, while a significant gross margin expansion to 39.7% has been partially offset by a rigid cost structure, resulting in a net margin of just 2.6%.
Petco Health and Wellness Company, Inc. (WOOF) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Jan'26 | Feb'25 | Feb'24 | Jan'23 | Jan'22 | Jan'21 | Feb'20 | Feb'19 |
|---|
| Sales/Revenue | 5.97B | 5.96B | 6.12B | 6.26B | 6.04B | 5.81B | 4.92B | 4.43B | 4.39B |
| Revenue Growth % | -1.32% | -2.53% | -2.22% | 3.63% | 3.94% | 18.03% | 10.95% | 0.96% | - |
| Cost of Goods Sold | 3.65B | 3.66B | 3.79B | 3.9B | 3.61B | 3.38B | 2.81B | 2.53B | 2.49B |
| COGS % of Revenue | - | 61.33% | 62% | 62.37% | 59.79% | 58.21% | 57.18% | 57.01% | 56.63% |
| Gross Profit | 2.32B | 2.31B | 2.32B | 2.35B | 2.43B | 2.43B | 2.11B | 1.91B | 1.9B |
| Gross Margin % | 38.81% | 38.67% | 38% | 37.63% | 40.21% | 41.79% | 42.82% | 42.99% | 43.37% |
| Gross Profit Growth % | - | -0.83% | -1.25% | -3.02% | 0.02% | 15.18% | 10.5% | 0.09% | - |
| Operating Expenses | 2.18B | 2.18B | 2.32B | 3.53B | 2.2B | 2.16B | 1.91B | 1.8B | 1.75B |
| OpEx % of Revenue | - | 36.65% | 37.89% | 56.5% | 36.47% | 37.2% | 38.87% | 40.5% | 39.76% |
| Selling, General & Admin | 2.18B | 2.18B | 2.32B | 2.31B | 2.2B | 2.16B | 1.91B | 1.78B | 1.73B |
| SG&A % of Revenue | - | 36.65% | 37.89% | 36.95% | 36.47% | 37.2% | 38.87% | 40.07% | 39.32% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 1.22B | 0 | 0 | 0 | 19M | 373.17M |
| Operating Income | 133.49M | 120.43M | 7.05M | -1.18B | 225.56M | 266.07M | 194.42M | 110.6M | -214.72M |
| Operating Margin % | 2.24% | 2.02% | 0.12% | -18.87% | 3.74% | 4.58% | 3.95% | 2.49% | -4.89% |
| Operating Income Growth % | - | 1608.03% | 100.6% | -623.28% | -15.23% | 36.85% | 75.79% | 151.51% | - |
| EBITDA | 330.99M | 317.14M | 206.78M | -979.53M | 419.39M | 438.5M | 369.26M | 284.14M | -27.72M |
| EBITDA Margin % | 5.55% | 5.32% | 3.38% | -15.66% | 6.95% | 7.55% | 7.51% | 6.41% | -0.63% |
| EBITDA Growth % | 12.9% | 53.37% | 121.11% | -333.56% | -4.36% | 18.75% | 29.96% | 1124.94% | - |
| D&A (Non-Cash Add-back) | 197.5M | 196.71M | 199.73M | 200.78M | 193.83M | 172.43M | 174.84M | 173.54M | 187M |
| EBIT | 146.25M | 146.53M | 15.56M | -1.17B | 213.92M | 279.79M | 177.53M | 110.94M | -214.76M |
| Net Interest Income | -121.72M | -124.89M | -139.82M | -147.5M | -100.61M | -77.33M | -218.43M | -252.68M | -243.32M |
| Interest Income | 8.03M | 6.3M | 3.71M | 3.4M | 1.03M | 62K | 653K | 335K | 420K |
| Interest Expense | 129.75M | 131.2M | 143.53M | 150.91M | 101.64M | 77.4M | 219.08M | 253.02M | 243.74M |
| Other Income/Expense | -121.78M | -105.1M | -116.35M | -127.51M | -100.3M | -52.79M | -235.98M | -250.24M | -243.78M |
| Pretax Income | 11.71M | 15.33M | -109.3M | -1.31B | 125.26M | 213.28M | -41.55M | -139.64M | -458.5M |
| Pretax Margin % | 0.2% | 0.26% | -1.79% | -20.91% | 2.08% | 3.67% | -0.84% | -3.15% | -10.44% |
| Income Tax | -13.36M | 6.27M | -7.48M | -27.61M | 35.35M | 53.47M | -3.34M | -35.66M | -45.84M |
| Effective Tax Rate % | -114.06% | 40.87% | 6.84% | 2.11% | 28.22% | 25.07% | 8.03% | 25.54% | 10% |
| Net Income | 30.27M | 9.07M | -101.82M | -1.28B | 90.8M | 164.42M | -26.48M | -95.87M | -413.79M |
| Net Margin % | 0.51% | 0.15% | -1.66% | -20.47% | 1.5% | 2.83% | -0.54% | -2.16% | -9.42% |
| Net Income Growth % | 207.34% | 108.9% | 92.05% | -1509.91% | -44.77% | 720.84% | 72.38% | 76.83% | - |
| Net Income (Continuing) | 25.07M | 9.07M | -101.82M | -1.28B | 89.91M | 159.81M | -38.22M | -103.98M | -413.79M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | -18.2M | -13.58M | -8.33M | 0 |
| EPS (Diluted) | 0.10 | 0.03 | -0.37 | -4.78 | 0.34 | 0.62 | -0.13 | -0.07 | -0.28 |
| EPS Growth % | 196.8% | 108.57% | 92.26% | -1505.88% | -45.16% | 576.92% | -97.87% | 76.54% | - |
| EPS (Basic) | - | 0.03 | -0.37 | -4.78 | 0.34 | 0.62 | -0.13 | -0.07 | -0.28 |
| Diluted Shares Outstanding | 290.5M | 286.15M | 273.41M | 267.55M | 265.95M | 265.34M | 210.68M | 1.46B | 1.46B |
| Basic Shares Outstanding | 285.63M | 279.56M | 273.41M | 267.55M | 265.52M | 265.19M | 203.72M | 1.44B | 1.46B |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying WOOF stock.
For fiscal year 2025, Petco Health and Wellness Company, Inc. (WOOF) reported total revenue of $5.96B. This represents a 35.7% increase compared to $4.39B in 2018.
Petco Health and Wellness Company, Inc. (WOOF) is profitable, generating $9.1M in net income for the fiscal year ending 2025 with a net profit margin of 0.2%.
Petco Health and Wellness Company, Inc. (WOOF) reported an operating income of $120.4M, resulting in an operating profit margin of 2.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Petco Health and Wellness Company, Inc. (WOOF) generated $2.31B in gross profit for the year, representing a gross profit margin of 38.7%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Leverage constrains strategic pivot
Metrics are mathematically derived from official filings.
Top-Line Stagnation Amidst Strategic Pivot
Petco's revenue growth has decelerated from a 1.2% increase in 2024Q3 to a flat 0.0% in 2026Q2, indicating the company's transformation strategy has yet to generate meaningful top-line momentum despite recent positive comp commentary.
The sequential deceleration in revenue growth, culminating in a flat quarter, suggests the company is struggling to expand its addressable market or capture share in a competitive landscape. This stagnation is particularly concerning given the high fixed-cost base of its physical service network, as revenue growth is critical to absorbing those costs and improving operating leverage. The lack of growth implies the 'health and wellness' platform pivot is not yet translating into accelerated customer acquisition or wallet share gains.
Gross Margin Recovery Masked by Operating Inefficiency
Gross margin expanded significantly from 34.7% in 2024Q4 to 39.7% in 2026Q2, yet operating margin remains below 3.5%, indicating that cost discipline in COGS is being offset by persistent overhead and service ramp-up expenses.
The 500 basis point improvement in gross margin over the last six quarters is a positive signal, likely reflecting better product mix, private-label penetration, or reduced promotional activity. However, the failure of this gross profit expansion to flow through to the bottom line—evidenced by operating margin peaking at just 3.2%—points to a structural issue with SG&A and the fixed costs of the veterinary clinic rollout. This disconnect suggests the company's cost structure is not yet optimized for its current revenue scale.
Operating Leverage Remains Elusive
Despite a $52.2 million year-over-year increase in gross profit from 2024Q2 to 2026Q2, operating income only grew by $45.3 million, demonstrating that incremental revenue is not generating proportional operating profit due to a rigid cost base.
The data shows that for every dollar of incremental gross profit generated over the two-year period, approximately 87 cents was consumed by higher operating expenses. This indicates a near-complete lack of operating leverage, which is a critical flaw for a company attempting a capital-intensive transformation. The implication is that the business model requires a significantly higher revenue base or a fundamental restructuring of its overhead to achieve meaningful profit expansion.
SG&A Discipline is the Primary Margin Lever
SG&A as a percentage of revenue has been reduced from 39.9% in 2024Q1 to 36.2% in 2026Q2, representing the sole driver of the company's path to profitability in the absence of revenue growth.
The consistent reduction in SG&A intensity is the most encouraging trend in the income statement, suggesting management is successfully controlling corporate overhead and store-level expenses. However, this cost-cutting appears to be reaching a point of diminishing returns, as the rate of improvement has slowed in recent quarters. With R&D at zero and COGS largely market-driven, further margin expansion will be exceptionally difficult without a renewed focus on revenue growth or a more aggressive rationalization of the store footprint.
The Pivot to Profitability in 2025
The period from 2024Q4 to 2025Q2 marks a clear operational inflection, where the company moved from consistent net losses to sustained, albeit thin, profitability, driven by a sharp improvement in gross margin.
This inflection was not driven by revenue growth, which remained negative, but by a decisive improvement in gross margin from the mid-30s to the high-30s. This suggests a successful shift in product mix, pricing strategy, or inventory management that has permanently reset the company's gross profit profile. The lasting impact is a new baseline of profitability, but the challenge has now shifted from achieving profitability to generating a sufficient return on the capital invested in the business.
The Margin Illusion and Leverage Trap
The narrative of margin expansion may be masking a core vulnerability: with a debt-to-equity ratio of 2.46 and net margin of just 0.2%, the company has virtually no buffer to absorb a consumer downturn or a rise in input costs.
Short-sellers would focus on the fact that the entire profitability story rests on gross margin improvement in a zero-growth environment, which is inherently unsustainable. The razor-thin net margin means any operational misstep, competitive pricing action, or increase in interest expense could immediately push the company back into losses. Furthermore, the high leverage constrains financial flexibility, potentially forcing management to choose between deleveraging and funding the growth of its veterinary platform, creating a strategic dilemma that could destroy long-term value.